Close Menu

chromosomal microarray

By partnering with telehealth provider PWNHealth, Lineagen wants to help children on the autism spectrum start treatment faster and qualify for more benefits.

Lineagen hopes to use PWNHealth's consumer-oriented model to expand access to its testing services for developmental delay and autism spectrum disorder.

Although the two studies seem to provide conflicting results on the impact of PGS, the "devil's in the details," according to an outside expert.

Invitae is interested in companies that can contribute positively to its revenues in the next two to three quarters, according to CEO Sean George. 

The acquisitions will enable Invitae to add reproductive health genetic testing to its portfolio and become what it calls a "comprehensive genomic information company." 

The firm reported $3.5 million in revenue for the three months ended Dec. 31, 2016, and $12.9 million for the full year.

CombiMatrix said the move will increase access to the test in the state for women experiencing recurrent pregnancy loss.

The company's testing was successful in more than 90 percent of cases over almost four years, and detected a wide variety of abnormalities.

Ambry's new lab provides a streamlined, automated workflow that has allowed the company to triple its daily testing volume since it opened more than four months ago. 

The company reported an 18 percent increase in the number of reproductive health tests completed during the quarter. 

Pages

23andMe has a holiday popup shop at a mall and could open additional stores, Bloomberg reports.

By studying koalas and a retrovirus that infects them, researchers may have uncovered a new sort of 'immune response' that occurs at the genomic level, Agence France Presse reports.

NPR reports that the first person in the US given a gene editing-based therapy for a genetic disorder is heading home.

In Science this week: ancient genomes reveal social inequality within individual households, new method for quantifying genetic variation in gene dosage, and more.